Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial ...

The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.13 per share. The biopharmaceutical company posted ...

Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Analysts are estimating that Syndax Pharmaceuticals will report an earnings per share (EPS) of $-1.11. Investors in Syndax Pharmaceuticals are eagerly awaiting the company's announcement, hoping for ...

Fintel reports that on October 24, 2024, UBS initiated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy ...

On Friday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $18.98 which represents a slight increase of $0.12 or 0.64% from the prior close of $18.86. The stock opened ...

Barclays analyst Peter Lawson assigned a Buy rating to Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...